CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE)

What this Trial Is About

The CHinese pulmOnary Embolism Multimodality Imaging-artifiCial intelligencE Study (CHOICE) is a prospective observational study conducted across multiple centers in China. It focuses on patients with pulmonary embolism (PE), including acute pulmonary embolism (APE), chronic thromboembolic pulmonary disease (CTEPD), and chronic thromboembolic pulmonary hypertension (CTEPH). The study aims to use artificial intelligence (AI) to identify imaging markers that help in early diagnosis, risk stratification, differential diagnosis, and prognosis of PE, a condition with significant health risks. The study collects imaging text data and raw imaging data from patients diagnosed with PE confirmed by computed tomography pulmonary angiography (CTPA), lung ventilation/perfusion (V/Q) scan, or pulmonary angiography. AI technology will process these images to provide new imaging markers and generate radiology reports with key imaging slices and evaluation results. The study includes different patient groups based on the stage and severity of PE and related conditions, such as those with acute symptomatic PE, chronic thromboembolic pulmonary disease with or without pulmonary hypertension, and other pulmonary vascular diseases. Participants will undergo multimodal imaging tests including CTPA, MRI, echocardiography, and V/Q scans. Researchers will study diagnostic rates of PE, risk stratification, disease severity, mortality, discordant case rates, AI detection failure, hospital stay length, time to diagnosis, and hospitalization costs over a two-year period. The study monitors participants' imaging data quality and follow-up, aiming to integrate AI tools into clinical practice to improve PE management and cost-effectiveness.

Chinese PE Multimodality Imaging Artificial Intelligence Study